沙棘干乳剂治疗肠易激综合征的临床观察

目的观察沙棘干乳剂治疗肠易激综合征的临床疗效及安全性。方法采用非盲法随机对照设计,将45例患者随机分为两组,并分别用沙棘干乳剂(治疗组30例)和得舒特(对照组15例)治疗,采用症状尺度表、大便性状表记录两组患者主要症状变化,并记录与药物相关的不良反应。结果总有效率治疗组为85.3%,对照组为73.3%。沙棘干乳剂在改善患者大便性状、减少腹泻患者排便次数、减少排便急迫感天数方面,其疗效均优于得舒特(P<0.05),同时未见与药物有关的不良反应。结论沙棘干乳剂治疗肠易激综合征疗效肯定,且无毒副反应。

Clinical Observation on Effect of Shajiganruji in Treating IrritabIe Bowel Syndrome

Objective To observe the clinical efficacy and safety of the Shajiganruji(SJ),in treating the irritable bowel syndrome (DIBS).Methods Randomized controlled open clinical trial design was adopted,45 patients were randomly divided into two groups, SJ and pinaverium bromide (PVB) were given as treated and control agent respectively. IBS scoring system (BSS),defecation state questionnaire (DSQ)were used to record the changes of the patients main symptoms before and after treatment. Results The total effective rate of SJ group was 85.9%,while that of PVB was 73.3%.CJT was superior in efficacy to that of PVB in improving stool quality, reducing defecation episodes of diarrheic patients, alleviating tenesmus symptoms, decreasing bellyache days and ameliorating abdominal distention. Any drug-related adverse reaction was not seen. Conclusion The efficacy of SJ in treating IBS is definite and without any toxic and adverse effects